Safety and Efficacy Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for GVHD Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Key Points

• Patients experienced fewer GVHD complications with ruxolitinib treatment, supporting its efficacy.
• The trial observed a 25% reduction in severe GVHD cases at the 6-month mark, indicating a positive outcome.
• Phase II trial involved older adults undergoing reduced intensity conditioning for allogeneic HCT.
• Findings highlight the importance of tailored treatment approaches for older patients undergoing transplant.